List view / Grid view
Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the fourth…
Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the fourth quarter and full year of 2014, which were highlighted by strong global sales for priority brands and important advances in the company’s immuno-oncology (I-O) portfolio.
Bristol-Myers Squibb Company announced that the U.S. Food and Drug…
6 January 2015 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) injection, for intravenous use...
Bristol-Myers Squibb Company announced plans to construct a new state-of-the-art,…
14 November 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced plans to construct a new state-of-the-art, large-scale biologics manufacturing facility in Cruiserath, County Dublin, Ireland, that will produce multiple therapies for the company’s growing biologics portfolio...
The appointment of Francis Cuss announced...
7 April 2013 | By Bristol-Myers Squibb Company
The appointment of Francis Cuss announced...
Bristol-Myers Squibb Company and Pfizer announced that the U.S. FDA…
2 January 2013 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Pfizer announced that the U.S. FDA approved ELIQUIS® (apixaban)...
The EC has approved ELIQUIS®...
20 November 2012 | By Bristol-Myers Squibb Company
The EC has approved ELIQUIS®...
The European Commission has approved FORXIGA™ (dapagliflozin) tablets...
14 November 2012 | By AstraZeneca
The European Commission has approved FORXIGA™ (dapagliflozin) tablets...
Sanofi & Bristol-Myers Squibb have restructured their long-term alliance...
3 October 2012 | By Bristol-Myers Squibb Company
Sanofi & Bristol-Myers Squibb have restructured their long-term alliance...
Frances Heller will join as Senior VP, Business Development, on…
28 September 2012 | By Bristol-Myers Squibb Company
Frances Heller will join as Senior VP, Business Development, on October 1...
AstraZeneca has made an initial payment of approximately $3.2 billion…
9 August 2012 | By AstraZeneca
AstraZeneca has made an initial payment of approximately $3.2 billion to Amylin Pharmaceuticals...
Bristol-Myers Squibb to acquire Amylin...
30 June 2012 | By AstraZeneca
Bristol-Myers Squibb to acquire Amylin...
Expansion of Together on Diabetes® initiative to China and India…
15 May 2012 | By Bristol-Myers Squibb Company
Expansion of Together on Diabetes® initiative to China and India ...
Bristol-Myers Squibb Company and AstraZeneca announced that the CHMP of…
20 April 2012 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and AstraZeneca announced that the CHMP of the EMA has recommended approval of FORXIGA® (dapagliflozin) tablets...
Bristol-Myers Squibb Company announced that its Board of Directors has…
24 January 2012 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced that its Board of Directors has elected Gerald L. Storch to the Board...
Bristol-Myers Squibb to acquire Inhibitex for $26.00 per share in…
7 January 2012 | By Bristol-Myers Squibb
Bristol-Myers Squibb to acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger...
